Is Alpha Teknova, Inc. overvalued or undervalued?

As of 11 August 2021, Alpha Teknova, Inc. has moved from a valuation grade of very expensive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued based on its financial metrics. Key ratios include a Price to Book Value of 4.03, an EV to EBITDA of -18.40, and a ROCE of -34.43%.
In comparison to its peers, Alpha Teknova's EV to EBITDA ratio of -16.66 is worse than Capricor Therapeutics, Inc., which stands at -7.47, and significantly underperforms CytomX Therapeutics, Inc., which has a positive EV to EBITDA of 7.98. The company's recent stock performance has been poor, with a year-to-date return of -36.77%, contrasting sharply with the S&P 500's gain of 2.44% during the same period, reinforcing the notion that Alpha Teknova is overvalued in its current state.